SPARCNSESun Pharma Advanced Research Company Limited· PharmaceuticalsMediumNeutral
Announced Wed, 22 Apr · 17:22 IST

Dilip S. Shanghvi has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Ownership Changes View source PDF

SPARC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-3.5%1-day move
₹143.45
prior close
₹143.82
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4-0.2+0.1+1.1-3.5+2.3+2.5+4.0-0.7-2.4+14.4+64.4+63.5+50.0
Up moveDown movePending
AI summary

Dilip S. Shanghvi, promoter of Sun Pharma Advanced Research Company (SPARC), has filed a declaration under SEBI Takeover Regulations confirming that as of March 31, 2026, he along with the promoter group and persons acting in concert has not created any new encumbrance (pledge or similar charge) on SPARC shares. The disclosure clarifies that no fresh pledges exist beyond those already reported earlier during the financial year. This is a routine annual compliance filing required under Regulation 31(4) to assure the market about promoter share encumbrance status.

Likely market impact

Neutral to slightly positive for shareholders — confirms that the promoter has not added new pledges on his SPARC holdings, reducing concerns about potential forced selling or margin pressure. The stock is unlikely to see any meaningful price reaction from this routine disclosure.